First time ACS in patients with on-target lipid levels: Inflammation at admission and re-event rate at follow-up

• Published in: European journal of clinical investigation 2024-12, Vol.54 (12), p.e14305
• Main Authors: Muñoz-García, Natàlia, Cordero, Alberto, Padro, Teresa, Mendieta, Guiomar, Vilahur, Gemma, Flores, Emilio, Badimon, Lina
• Format: Article
• Language: English
• Subjects: Acute Coronary Syndrome - blood; Aged; Arteriosclerosis; Atherosclerosis; Biomarkers - blood; Biomarkers - metabolism; C-Reactive Protein - metabolism; Chest; Chest Pain; Cholesterol, LDL - blood; Cholesterol, LDL - metabolism; Dyslipidemia; Dyslipidemias - blood; Ejection fraction; Female; Follow-Up Studies; Glycoproteins; Heart; Humans; Inflammation; Inflammation - blood; Interleukin 6; Interleukin-6 - blood; Leukocytes (neutrophilic); Lipids; Lipoprotein(a) - blood; Lipoprotein(a) - metabolism; Lipoproteins; Low density lipoprotein; Lymphocytes; Male; Middle Aged; NMR; Nuclear magnetic resonance; Pain; Recurrence; Stroke Volume - physiology; Ventricle
• ISSN: 0014-2972; 1365-2362; 1365-2362
• DOI: 10.1111/eci.14305

Dyslipidaemia, inflammation and elevated Lp(a) levels are associated with the progression of atherosclerosis. This study investigates whether patients with a first-time presentation of chest pain and on-target LDL-C levels and intermediate FRS/ESC-Score risks, display a high inflammatory burden linked to myocardial injury and whether inflammation at admission affects the re-event rate up to 6 years follow-up. Blind assessments of novel inflammatory markers such as Glycoprotein A and B via nuclear magnetic resonance (NMR), cytokines, hsCRP, Neutrophil-to-Lymphocyte ratio (NLR) and Lipoprotein(a) levels were examined. Out of 198 chest pain patients screened, 97 met the inclusion criteria at admission. cTnI(+) patients (>61 ng/L) with elevated Lipoprotein(a), showed significantly increased levels of Glycoprotein A and B, hsCRP, IL-6, a high NLR and a reduced left ventricular ejection fraction (%) compared to cTnI(-) individuals. Those patients, with a higher inflammatory burden at hospital admission (hsCRP, IL-6, Glycoprotein A and B, and Lipoprotein(a)) had a higher re-event rate at follow-up. Inflammation and Lipoprotein(a) levels were particularly prominent in patients presenting with reduced left ventricular ejection fraction. Notably, Glycoproteins A/B emerge as novel markers of inflammation in these patients. Our study highlights the significantly higher impact of inflammatory burden in patients with chest pain and high level of myocardial damage than in those with lower myocardial affectation, even when they all had lipid levels well controlled. Inflammation at the time of admission influenced the re-event rate over a follow-up period of up to 6 years.